Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01720264 · ClinicalTrials.gov registry record · Phase 2
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
A Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin, sponsored by Sherif S. Far.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT01720264: Completed Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin, sponsored by Sherif S. Far.
NCT01720264 is a Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin that has completed, run by Sherif S. Far. The registered enrollment target is 15 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01720264, a Phase 2 study of Acute Myeloid Leukemia and Lymphoma, Non-Hodgkin, has completed, sponsored by Sherif S. Far.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Primary Outcome
Percent of patients and the 95% Binomial Confidence interval who were able to achieve neutrophils engraftment (defined as the date of the first of three consecutive ANC values obtained on different days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l) by 30 days following transplant.
Conditions Studied
Interventions
- DRUG Sitagliptin
Study Locations (2)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
New York
- New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-11-02 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 2 |
What the finished NCT01720264 record still lists
NCT01720264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (87% lower).
The record links to 5 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Sitagliptin is the first listed.
NCT01720264 reports a single indexed study location in Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT01720264 about?
NCT01720264 is a clinical study titled "Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant". The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
What is the current status of trial NCT01720264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-11-02. Estimated completion is 2017-12-15.
What conditions does trial NCT01720264 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Lymphoma, Non-Hodgkin, Acute Lymphoid Leukemia, Leukemia, Myelogenous, Chronic, Hematopoetic Myelodysplasia.
What interventions are being tested in trial NCT01720264?
The interventions under investigation include: Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01720264?
This trial is sponsored by Sherif S. Far, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01720264 being conducted?
This trial has 2 study locations across Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01720264's enrollment target sits among peer trials
15 274th of 306 higher than 24 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI